✕
Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
 简体中文
(Simplified Chinese) 繁體中文
(Traditional Chinese)
CLINICAL
Our goal is to create measurable differences in global health.

MediBeacon is a medical technology company focused on advancing the use of fluorescent tracer agents and transdermal detection technology to provide vital and actionable assessment of organ function. New insights that have direct relevance to treatment decisions are the goal.

Accurate physiological measurements made at the point of care, are vital in the hospital as well as in the management of chronic diseases. There are vast opportunities to use this data to help improve disease treatments in situations where multiple unknowns make clinical decisions a challenge.
MediBeacon products are in various stages of clinical development.
First in-human clinical studies are underway to establish the feasibility of fluorescent tracer agent-based systems to quantify the permeability of the gastrointestinal tract in patients with active Crohn’s Disease.
Maintenance of intestinal barrier function is important for our health, and dysfunction is a risk factor for a variety of disorders and diseases.
- Clinical and Translational Gastroenterology, Julia König et al., Human intestinal barrier function in health and disease, September 14, 2016

Accurate physiological measurements made in real-time and at the point of care could be of utmost value in the hospital as well as in the management of chronic diseases. Fluorescent tracer agent-based monitoring systems are well positioned to provide an assessment of GFR, quantification of GI permeability, enhanced visualization of the vasculature during ocular angiography, and identification of the ureters during abdominal surgeries.*
At MediBeacon we strive to create measurable differences that impact global health. Evidence of our advances can be found in the numerous issued global patents.
MediBeacon developments have been the subject of numerous publications including peer-reviewed and proceedings papers, as well as review articles and posters presented at global scientific conferences.
Transdermal assessment of Glomerular Filtration Rate (tGFR) is well established in preclinical research. MediBeacon technology is used by leading medical schools, academic centers, research institutes, contract research organizations and pharmaceutical companies worldwide to enhance preclinical assessment of kidney therapeutics, evaluate nephrotoxicity, and gain fundamental understanding of kidney function in animals.

United States
MediBeacon Inc.
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 269-5808

Germany
MediBeacon GmbH
Cubex41
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
P: +49 (0)621-150283-15

Greater China
(Exclusive Commercial Partner)
Huadong Medicine Co., Ltd
Telephone: 4008-269-985
+86-(0)571-89908581
Zip: 310011
Address: No.866. Moganshan Road, Hangzhou, Zhejiang Province, China
Email: info@eastchinapharm.com

Science How it Works R&D Platform Product Pipeline Patent Estate Preclinical Clinical Focus Areas Nephrology Gastroenterology Ophthalmology Surgery In Discovery
Publications MediBeacon Publications Preclinical Publications Industry Literature Company History People By the Numbers Quality Commitment News/Media Contact Get Updates Investors General Questions

*MediBeacon products are in various stages of clinical development and not yet approved for human use.

Terms and Conditions | Privacy Policy | © 2024 MediBeacon All Rights Reserved.

COOKIE CONSENT: We use cookies and similar technologies to recognize your repeat visits and preferences, as well as to analyze traffic, among other things. To learn more about cookies, view our Privacy Policy. By clicking “I Accept” on this banner, or using our site, you consent to the use of cookies unless you have disabled them.